Mates Sharon

ITCI CEO Mates Sharon sells 102.7K shares for $8.7M in four transactions at $84–$86 range.

On December 4–5, 2024, Sharon Mates executed four separate sales totaling 102.7K shares for $8.7M at a blended average price of $84.93, reducing her holdings from 1.17M to 1.07M shares (-8.8% reduction). The company is unprofitable (net income $-26.3M over its latest full fiscal year) despite strong revenue growth of +85.5%, and trades at $84.55 currently versus the $84–$86 range at which the CEO sold, placing the sales near recent strength. Notably, Mates' prior ITCI sells (five transactions in late August 2024) showed no well-timed outcomes at the 90-day mark, with all five generating positive 90-day returns after sale (+18.1% to +19.5%), indicating the stock rose substantially after her previous sell decisions. Her cross-ticker track record shows 0.00% well-timed rate across 20 prior sells, with average 90-day returns of +12.4% after sale—again reflecting that her prior liquidations have been followed by gains rather than declines. The current sale occurs at a level near the 52-week high of $91.57 but already 7.7% below it, in a stock that is down 5.5% over 30 days yet up 15.0% over 90 days.

CEO Sharon Mates sold 70,000 ITCI shares for $5.1M across 4 transactions Aug 29-30 at blended $72.70; retains 1,070,329 shares post-sale.

Sharon Mates, Chairman and CEO of Intra-Cellular Therapies, executed 4 separate sales totaling 70,000 shares for $5,089,235.51 at an average price of $72.70 on August 29–30, 2024. The company remains unprofitable (net income $-16,220,000.00 in the latest full year) despite strong revenue growth of 85.5%, and the stock currently trades at $73.28, only 9.4% below its 52-week high. Following the sale, Mates retains 1,070,329 shares, representing a -6.1% reduction in his pre-transaction holdings. The timing and magnitude of this multi-transaction filing warrant investor attention: the sales occurred near the stock's peak valuation and at a point where the 30-day change stands at -6.9%, suggesting prices were elevated when the CEO chose to liquidate. This activity is particularly notable given that the company is unprofitable and the CEO's own recent trading history at ITCI shows 5 prior sells in just 3 days (August 26–28), signaling a pattern of consistent liquidation at or near current price levels.

Sharon Mates (CEO) sold 95,925 shares for $7.1M across 5 transactions Aug 26-28 at blended average $73.54, retaining 1.07M shares

Sharon Mates, Chairman and CEO of Intra-Cellular Therapies, Inc., executed 5 separate sales totaling 95,925 shares for $7,054,085.49 between August 26–28, 2024, at prices ranging from $72.74 to $74.59 (blended average $73.54). The sale represents an 8.2% reduction from pre-transaction holdings of 1,166,254 shares, leaving him with 1,070,329 shares post-transaction. The current stock price of $72.77 is 10.0% below the 52-week high of $80.84 and down 6.9% over the past 30 days, though it has gained 10.8% over 90 days. The company reported Q1 revenue of $161,388,000 with a net loss of $16,220,000, though full-year revenue growth reached 85.5%. The context of back-to-back sales within three days warrants examination of whether this reflects scheduled portfolio activity, capital allocation priorities, or a shift in positioning by the CEO at a company that remains unprofitable despite strong revenue growth.

Intra-Cellular Therapies CEO Sharon Mates sold 121,073 shares in 7 transactions (Aug 21–23, 2024) for $9,086,738.16 at blended avg $75.05

Sharon Mates, CEO of Intra-Cellular Therapies, executed 7 separate sales over three trading days (August 21–23, 2024), offloading 121,073 shares for a combined $9,086,738.16 at a blended average price of $75.05. This represents a 10.2% reduction in her post-transaction holdings from 1,191,402 shares to 1,070,329 shares. The sales occurred near the 52-week high of $80.84 and at prices ranging from $74.46 to $77.98, which is notably higher than the current price of $74.48. Mates' same-ticker history at ITCI shows 5 prior sales since early March 2024, with subsequent 30- and 90-day performance that was consistently positive (ranging from +0.1% to +3.8% at 90 days), meaning none of those prior sales preceded a decline—none were well-timed by the sell-timing definition. The company reported $-16.2M net income in its latest quarter and remains unprofitable on a full-year basis, despite strong revenue growth of 85.5% year-over-year, signaling continued operational losses underlying the recent price strength.